Biopharmaceutical Single-Use Bioprocessing Market

The biopharmaceutical single-use bioprocessing market is worth USD 17,484.0 million in 2025 and reaches USD 43,327.1 million by 2035, compounding at 9.50% a year. The figure is built bottom-up: roughly 186,000 bioprocess batches run in 2025 using single-use upstream and downstream systems across monoclonal antibodies, vaccines, cell and gene therapies and other biologics, at an average single-use consumable spend of USD 94,000 per batch covering bags and mixers, single-use bioreactors, filtration and chromatography consumables, and tubing, connectors and sensors, triangulated against supplier revenue, biologics production volumes and facility capacity. Batch count grows 8.2% a year as biologics pipelines expand and single-use penetration rises, while spend per batch rises 1.2% a year as assemblies become more integrated and sensor content increases. This study sits within our pharmaceutical manufacturing services coverage and follows the published Douglas Insights methodology.

What did the destocking cycle reveal about this market?

That underlying demand and supplier revenue can diverge sharply for years, and that a forecast built on supplier revenue alone will misread both the boom and the correction. During the pandemic, vaccine and therapeutic manufacturing consumed single-use components at unprecedented rates, supply ran short, lead times stretched to many months, and biomanufacturers responded rationally by ordering far ahead of need and building safety stock. When pandemic production wound down and supply normalised, customers held inventory sufficient for many months of consumption and simply stopped ordering while they worked through it. The leading suppliers reported revenue declines across several consecutive quarters even though the number of batches being run was broadly stable and in many segments still rising. Recovery arrived as inventories normalised, not as demand recovered, because demand had never fallen much. The lesson for anyone using this market is that consumption, meaning single-use content actually used in batches, is the correct measure of the underlying business, while supplier shipments oscillate around it with inventory swings. This report models consumption, and the exclusive chapter tracks the inventory position separately so that the two are not confused.

What does this market include?

This study covers single-use and disposable systems used in the manufacture of biological medicines. Bags, containers and mixing systems cover the two and three dimensional biocontainers used for media and buffer preparation, storage, transport and mixing, the highest volume category. Single-use bioreactors and assemblies cover the disposable bioreactor bags and the complete single-use assemblies used for cell culture, together with the reusable hardware platforms where sold as part of a single-use system. Filtration and chromatography consumables cover sterile and virus filters, depth filtration, single-use tangential flow cassettes, prepacked chromatography columns and membrane adsorbers used in purification. Tubing, connectors, sensors and sampling cover the fluid path components, aseptic connectors and disconnectors, single-use pressure, temperature, pH and dissolved oxygen sensors, and sampling systems. Stainless steel bioreactors and fixed equipment, chromatography resins sold for reusable columns, laboratory scale plastics and fill finish consumables sit outside the boundary.

Why did single-use win over stainless steel?

Because it removed the most expensive and slowest parts of running a biologics facility, which were cleaning and validating the equipment between batches. A stainless steel bioreactor must be cleaned in place and sterilised in place after every run, which requires purified water and steam systems, extensive piping, and cleaning validation that must demonstrate no carryover between products, all of which consumes time, utilities and capital. A single-use system arrives sterile, is used once and discarded, so turnaround between batches collapses and the risk of cross contamination between products is largely eliminated, which is decisive for multi product facilities and contract manufacturers switching between client molecules. Capital cost falls because the steam and cleaning infrastructure is not needed, and a facility can be built and brought into operation faster. The trade offs are real: consumable costs recur on every batch, scale is limited because single-use bioreactors have practical size ceilings well below the largest stainless steel vessels, leachable and extractable substances from plastics must be characterised, and supply depends on a small number of suppliers. For the growing majority of biologics, produced at modest volumes in multi product settings, those trade offs clearly favour single-use, and only the highest volume commercial products remain firmly stainless steel territory.

What drives demand?

The first driver is the biologics pipeline. Monoclonal antibodies, bispecifics, antibody drug conjugates, fusion proteins and vaccines dominate new approvals and late stage development, and nearly all of them are manufactured using single-use systems at clinical and increasingly at commercial scale.

The second driver is cell and gene therapy. These modalities are manufactured in small batches, often per patient in autologous therapies, and are almost entirely single-use because the batch sizes, aseptic requirements and product diversity make fixed equipment impractical.

The third driver is contract manufacturing growth. Contract development and manufacturing organisations switch between client products constantly, and single-use systems are what make that switching economic, so outsourcing growth translates directly into single-use consumption.

The fourth driver is biosimilars and emerging market capacity. Biosimilar production and new biologics capacity in Asia, Latin America and the Middle East is being built predominantly on single-use platforms because they allow faster facility start up at lower capital cost.

What could restrain growth?

Three restraints are modelled. Inventory cycles are the first and have already been demonstrated: when customers build safety stock and then consume it, supplier revenue swings far more than underlying consumption, which makes the market appear more volatile than the business it serves. Scale limits are second: single-use bioreactors top out at sizes that are adequate for most biologics but insufficient for the highest volume products, and continuous processing and intensification may reduce the number of batches required for a given output, lowering consumable demand per gram of product. Supply chain and geopolitical risk is third: the sector depends on a small number of suppliers for critical components, and legislative initiatives restricting certain foreign biotechnology suppliers in the United States have prompted sponsors to requalify supply chains, which slows decisions and adds cost.

Which product categories carry the revenue?

Bags, containers and mixing systems lead with 32% of 2025 revenue, USD 5,594.9 million, the highest volume category consumed across both upstream and downstream operations, including media and buffer preparation that surrounds every batch. Filtration and chromatography consumables hold 28%, USD 4,895.5 million, where sterile and virus filtration are regulatory requirements on every product and where single-use purification formats are gaining ground against reusable systems. Single-use bioreactors and assemblies account for 26%, USD 4,545.8 million, the most technically differentiated category and the one where supplier platform lock in is strongest. Tubing, connectors, sensors and sampling contribute 14%, USD 2,447.8 million, and grow fastest as single-use sensors replace reusable probes and as aseptic connection technology becomes more sophisticated. Each category is modelled through 2035 by modality and region.

Where is single-use consumed?

North America leads with 42% of 2025 revenue, USD 7,343.3 million, growing 8.7% a year, on the largest concentration of biologics development and manufacturing, a deep contract manufacturing sector and the majority of cell and gene therapy activity. Europe holds 30%, USD 5,245.2 million, at 9.0%, with substantial biologics manufacturing in Ireland, Germany, Switzerland, Belgium and the Netherlands and a strong contract manufacturing presence. Asia Pacific holds 22%, USD 3,846.5 million, and grows fastest at 11.4%, driven by South Korean and Chinese contract manufacturing scale, Indian biosimilar production and Japanese biologics manufacturing, with the pace in China affected by the supply chain requalification pressures noted above. Latin America contributes USD 524.5 million at 9.4%, the Middle East USD 349.7 million at 10.6% on pharmaceutical localisation, and Africa USD 174.8 million at 9.8% on vaccine manufacturing capacity initiatives. Six regional models sum to the global figure, with country tables in the Excel model.

Who supplies single-use bioprocessing?

Four suppliers dominate. Cytiva, part of Danaher, supplies bioreactors, bags, chromatography and filtration across the full process, and Danaher’s ownership of Pall adds substantial filtration capability. Sartorius holds a leading position particularly in single-use bioreactors, bags and filtration, with the most concentrated exposure to this market among the majors. Thermo Fisher Scientific supplies bags, bioreactors and fluid handling at scale, and MilliporeSigma, the life science business of Merck KGaA, is strong in filtration and increasingly in upstream systems. Around them, Repligen specialises in filtration and chromatography formats, Saint-Gobain and Avantor supply tubing and fluid path components, and Entegris and Corning supply specialised components. Chinese suppliers have grown rapidly serving domestic manufacturers, which has been a significant development given the supply concentration elsewhere. The competitive chapter profiles platform breadth, qualification positions within approved commercial processes, manufacturing redundancy and regional supply capability.

How is single-use content priced?

Single-use spend averages USD 94,000 per batch in 2025, and that figure varies enormously by modality and scale. A clinical scale antibody batch in a small bioreactor consumes a modest set of bags and filters. A commercial scale batch at the upper end of single-use bioreactor capacity consumes far more, particularly in buffer preparation and downstream filtration. A viral vector batch for gene therapy may carry very high consumable cost relative to its volume because of the complexity of the purification and the value of the product. Pricing is dominated by qualification lock in: once a single-use component is qualified into an approved commercial manufacturing process, changing it requires regulatory notification and often additional validation, so a sponsor rarely switches supplier for price alone and suppliers compete intensely for the design in at clinical stage. Supply agreements increasingly include dual sourcing requirements, a direct consequence of pandemic shortages, which gives secondary suppliers qualification opportunities they previously lacked. The pricing chapter publishes spend per batch by modality, scale and process stage.

How do the scenarios diverge by 2035?

The base case carries 8.2% batch growth and 1.2% growth in spend per batch for a 9.50% revenue CAGR and USD 43,327.1 million in 2035. The intensification scenario, in which continuous processing and higher titre processes reduce the number of batches needed per gram of product, sets the legs at 5.6% and 0.6%, landing near USD 31,440 million. The modality-expansion scenario, in which cell and gene therapy scales commercially and biosimilar and emerging market capacity grows faster, sets them at 10.6% and 2.4%, carrying the market past USD 59,500 million. Each 1-point change in batch growth moves the 2035 figure by roughly USD 3,970 million.

Which rules and standards apply?

Three layers matter. Good manufacturing practice regulation comes first: single-use components become part of the manufacturing process for an approved medicine, so their qualification, change control and supplier oversight fall under manufacturing regulation, and any change to a qualified component requires assessment and in many cases regulatory notification. Extractables and leachables requirements are second and are specific to this technology: plastics in contact with product can release substances, so suppliers must characterise extractables under defined conditions and manufacturers must assess leachables in their specific process, with industry standardised testing protocols having developed to make this manageable. Supply chain and foreign supplier legislation is third: legislative measures in the United States restricting certain biotechnology suppliers of concern have prompted sponsors to review and in some cases replace suppliers, which affects the geographic distribution of both supply and contract manufacturing. The regulatory chapter maps these requirements and the qualification implications of supplier change.

What does the move to continuous processing mean?

Continuous and intensified bioprocessing is the most important technical trend for the long run shape of this market, and its effect cuts in two directions. In a conventional batch process, each production run is a discrete event with its own setup, its own set of consumables and its own downtime, so consumable demand scales with the number of batches. Intensified processes achieve much higher cell densities and product titres, so more product comes from each run, and continuous processes run for extended periods rather than as discrete batches, both of which reduce the number of discrete setups and therefore the consumables associated with each. Taken alone, that would lower single-use demand per gram of medicine produced. The countervailing effect is that continuous processing is itself heavily single-use, since the extended runs, perfusion systems and connected downstream operations are almost always built from disposable components, and the specialised consumables involved carry higher value than the conventional equivalents. The net effect over this forecast is modest pressure on batch counts partly offset by richer content per run, which is why the base case carries spend per batch rising while batch growth moderates in the intensification scenario. Adoption is gradual, since reengineering an approved commercial process requires regulatory work that sponsors undertake only for new products or major lifecycle changes.

Douglas Exclusive: the consumption versus shipment tracker

This report tracks, by product category and region, estimated single-use consumption derived from batch activity, supplier shipments from disclosed revenue, the implied inventory build or drawdown between them, lead times by category, and the dual sourcing qualifications completed since supply normalised, allowing licensees to distinguish underlying demand from inventory driven revenue swings and to anticipate the next cycle. Licence holders receive it as a maintained tab in the Excel model.

Methodology and receipts

The model is built bottom-up from batches: biologics production by modality, scale and region, single-use penetration by process stage and facility type, consumable content per batch by modality and scale, contract manufacturing share, and realised pricing from supplier disclosures, cross checked against supplier revenue and adjusted for inventory movements, with stainless steel equipment, resins for reusable columns, laboratory plastics and fill finish consumables excluded. Every figure carries a numbered source and a confidence grade in the fact sheet above, and the working model ships with every licence. The next scheduled review of this study is September 2027.